Choi Y, et al. - Researchers used a large-scale, multicenter, prospective cohort registry to assess how renin–angiotensin system (RAS) blockers (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) impact the clinical outcomes over the long-term in 5,722 patients with stable coronary artery disease (SCAD) without heart failure (HF) who had percutaneous coronary intervention (PCI) with drug-eluting stent. Two patient groups were formed based on the use of RAS blockers after PCI: a RAS blocker group and a no RAS blocker group. Excluded patients were those with left ventricular ejection fraction less than 50% and history of HF or myocardial infarction. They found RAS blockers significantly reduced the risk of major adverse cardiovascular event and all-cause death during a median follow-up of 29.7 months. Overall, they concluded that, in patients with SCAD without HF who had PCI, RAS blockers, as preventive therapies, effectively reduced long-term cardiovascular events.